MedTrace Logo

Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001)

NCT04754776 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-05-19

No results posted yet for this study

Summary

Phase I open label, non-randomised dose escalation study on healthy UK volunteers aged from 18 to 50 years to assess the safety and immunogenicity of ChAdOx1 RVF

Conditions

  • Rift Valley Fever

Interventions

BIOLOGICAL

ChAdOx1 RVF

Single dose of ChAdOx1 RVF

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Principal Investigators

  • Adrian VS Hill, Prof · Jenner Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-11
Primary Completion
2022-04-06
Completion
2022-04-06

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04754776 on ClinicalTrials.gov